Skip to content

Molecular Mechanisms and Diagnosis of Mastocytosis

Investigation of Cellular and Molecular Pathologic Mechanisms in Mast Cell Disorders.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00336076
Enrollment
136
Registered
2006-06-12
Start date
2004-07-31
Completion date
2009-07-31
Last updated
2016-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mastocytosis

Keywords

Mast cell disease, Anaphylaxis, c-kit, Mutation, Mastocytosis (suspected or proven)

Brief summary

Mastocytosis is a disorder characterized by presence of excessive numbers of mast cells in skin, bone marrow and internal organs. It can affect both children and adults, males and females and individuals from all ethnic backgrounds, although precise demographic information about the affected populations is not available as it is a rare disorder. Mastocytosis in children is generally limited to the skin and follows a self limited course, while it is a disorder of the hematopoietic stem cell associated with somatic mutations of the c-kit gene in most patients with adult-onset of disease. There is no known curative therapy for most patients with systemic mastocytosis. Recent research studies identified several subtypes of disease with distinct clinical and pathologic features, however, a precise understanding of the incidence as well as molecular pathology of different disease subtypes is lacking. This study aims to examine molecular and cellular pathological aspects of disease in patients with mastocytosis and correlate findings with clinical presentation and prognosis. Patients will undergo a routine history and physical examination, and diagnostic tests will be ordered as dictated by each patient's clinical presentation. Blood and bone marrow will be obtained for diagnostic and research purposes. Genetic analysis of the c-kit gene regulating mast cell growth and differentiation will be performed. It is hoped that findings obtained from this study will help to design novel therapies for mastocytosis and other disorders in which mast cells play a critical role.

Interventions

5-8 cc blood or bone marrow was additionally collected for analysis during diagnostic procedures. No assigned interventions.

Sponsors

University of Michigan
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Confirmed or suspected diagnosis of mastocytosis. * Ability to give informed consent (by the patient or legal guardian if minor)

Exclusion criteria

* Inability or not willing to provide informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of the patients with clonal and non-clonal mast cell disorders1 weekPatients were categorized into one of the clonal and non-clonal mast cell disorder categories after availability of diagnostic data

Secondary

MeasureTime frameDescription
Proportion of KIT D816V mutation in blood, bone marrow and sorted mast cells1 weekKIT D816V mutation was assessed in patient samples containing various proportions of neoplastic mast cells.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026